David Lyden

David Lyden is a Professor at Weill Cornell Medicine, holding the Stavros S. Niarchos Professorship in Pediatrics and Cell and Developmental Biology. He is a key faculty member in the Graduate School of Medical Sciences and maintains a strong research partnership with the Sloan Kettering Institute. His laboratory is dedicated to understanding the systemic effects of cancer, particularly through the lens of extracellular vesicles and particles (EVPs).

Dr. Lyden's research focuses on cancer metastasis, with a central theme on how primary tumors secrete extracellular vesicles to establish the pre-metastatic niche (PMN) in distant organs. His lab was the first to define the PMN concept and demonstrate that tumor-derived exosomes and EVPs drive vascular leakiness, immunosuppression, and recruitment of bone marrow progenitor cells. His groundbreaking discovery that exosomal integrins dictate organ-specific metastasis has reshaped understanding of metastatic tropism. The lab also identified a novel abundant particle, the exomere, using asymmetric-flow field-flow fractionation. Current projects emphasize EVP biogenesis, cargo packaging, biomarker discovery for early detection, and EV-based theranostics.

His publications from 2005 to 2024 reveal a sustained trajectory of high-impact research in Nature, Cell, and Nature Medicine. These works collectively highlight his leadership in elucidating the molecular mechanisms of pre-metastatic niche formation, multi-organ metastasis, and cancer-induced systemic dysfunction. The articles span topics from fundamental discoveries in metastasis to translational applications in biomarker development and metabolic reprogramming.

Dr. Lyden has received extensive recognition through his influential publications and leadership in the field, although specific awards are not listed in the text. His research is supported by major grants enabling advanced proteomic, bioinformatic, and imaging studies. He mentors students and postdoctoral fellows, contributing to training the next generation of cancer biologists.

His laboratory, known as the VIVO Lab, employs cutting-edge technologies including asymmetric-flow field-flow fractionation, mass cytometry, and super-resolution microscopy to characterize extracellular vesicles and their role in cancer progression. The team collaborates extensively within the Tri-Institutional network, including Memorial Sloan Kettering and Rockefeller University, fostering a highly interdisciplinary research environment.